On this basis, we hypothesized that the co-expression of S100A2 and PD-L1 in pancreatic cancer might be based on the activation of the S100A2-Akt-PD-L1 signaling pathway. This evidence concerns the gene S100A2 and familial pancreatic carcinoma.